Santaris announced an expanded deal with Pfizer granting the latter rights to continue to develop its RNA-based therapies. Pfizer also agreed to pay up to $600 M in milestone payments and royalties on as many as 10 therapeutics should they reach the market.
This is a continuation of the deal struck between Santoris and Wyeth back in 2009 prior to Pfizer's acquisition of Wyeth. A Pfizer spokesman said the company was encouraged by the progress of its oligonucleotide collaboration with Santoris and are eager to explore the expanded partnership for new RNA-based drugs.
Posted by Bruce Lehr Jan 5th 2011.